Skip Navigation
Search Menu

 
Print This Page
Share this page: More
 

Search Results

A total of 40 matching records were found.

J08130
Cytokine Expression During Radiation Therapy for Breast Cancer

J11105
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

J11155
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer

J1137
An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors

J12121
A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands

J1281
J1281, A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

J1284
Pre-operative Paravertebral Blocks to Decrease Post-operative Pain Following Mastectomy with Immediate Tissue Expander Reconstruction

J13104
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)

J13119
J13119; A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

J1349
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)

J14144
J14144-Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced/Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma

J14166
Prospective evaluation of high-dose (8 g/m2) systemic methotrexate in patients with breast cancer and leptomeningeal metastasis

J1428
A randomized multicenter pivotal study of CDX-011 (CR011-vcMMAE) in patients with metastatic, GPNMB over-expressing, triple-negative breast cancer

J1480
My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents (Protocol Number: ML28897/PRO 02)

J15184
J15184 - A phase Ib, open-label, dose-escalation study of the safety and pharmacology of GDC-0919 administered with Atezolizumab in patients with locally advanced or metastatic solid tumors

J15221
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (NCI# 9844)

J1541
Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies (Protocol CPDR001X2101)

J1564
“The IDEA Study (Individualized Decisions for Endocrine therapy Alone): A prospective, single-arm cohort study of patients receiving endocrine therapy alone (without radiotherapy) after breast conserving surgery for early-stage, post-menopausal breast cancer patients whose tumors have favorable biologic features”

J1581
STM-03: Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

J16108
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589)

J16121
Improving Outcomes for Younger Breast Cancer Survivors: A Phase III Randomized Trial Targeting Behavioral Symptoms in Younger Breast Cancer Survivors. The Pathways to Wellness (PTW) Study

J1677
J1677- A Phase 1/2a Study of BMS-986179 Administered in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors

J1681
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors

J1696
J1696 - A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study Of The Efficacy And Safety Of Trastuzumab Emtansine In Combination With Atezolizumab Or Atezolizumab-Placebo In Patients With Her2-Positive Locally Advanced Or Metastatic Breast Cancer Who Have Received Prior Trastuzumab And Taxane Based Therapy

NCTNA011104
A011104 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

NCTNA011202
A011202 A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

NCTNA011401
A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

NCTNA221405
A221405 A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

NCTNB51
B51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

NCTNB55
B55 A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (D081CC00006)

NCTNE1Z11
E1Z11 A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NCTNE2112
E2112 A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer

NCTNEA1131
EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy versus Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

NCTNEAY131
EAY131 Molecular Analysis for Therapy Choice (MATCH)

NCTNS1207
S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu-Negative Breast Cancer

NCTNS1418
S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than / equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

TBCRC026
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer

TBCRC030
A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker (TBCRC 030)

TBCRC031
A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (“AC”) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations – The INFORM BRCA 1/2 Study: Investigation of Neoadjuvant Chemotherapy for Mutation Carriers: BRCA1/2 (TBCRC 031)

TBCRC034
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy (TBCRC 034)

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

 

NCI CCC